Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Personalized Brain “Pacemakers” Could Help Patients with Hard-To-Treat Epilepsy

By HospiMedica International staff writers
Posted on 28 Oct 2025

Epilepsy affects more than 50 million people worldwide, and nearly one-third of them do not respond to available medications. More...

For many patients, seizures originate in brain areas responsible for essential functions like movement, speech, or vision, making surgical removal impossible. Current brain stimulation devices have offered only limited relief. Now, a personalized deep brain stimulation (DBS) therapy that adapts to each patient’s unique brain wiring is offering new hope for those with treatment-resistant epilepsy.

The research by a multidisciplinary team comprising physicians, neuroscientists, and bioengineers from the University of Pittsburgh (Pittsburgh, PA, USA) and UPMC (Pittsburgh, PA, USA) marks a major advance in developing individualized neurostimulation therapies for epilepsy patients who are not candidates for medication or surgery.

Unlike existing FDA-approved DBS systems that stimulate only one portion of the thalamus — the anterior nucleus — this new technique identifies and targets the exact area of the thalamus most strongly connected to the seizure-generating zones in the patient’s cerebral cortex. Researchers achieved this precision by combining advanced imaging with intracranial recordings to map the brain’s communication pathways in unprecedented detail.

The team analyzed data from 41 patients with drug-resistant epilepsy, creating detailed connectivity maps between seizure-prone regions of the cerebral cortex and different thalamic areas. When the researchers applied electrical stimulation to the thalamic region most closely linked to cortical seizure activity, patients experienced significant seizure reduction. Those who received long-term implants saw an average decrease in seizure frequency of nearly 90%, with some remaining seizure-free for extended periods.

This study, published in Nature Communications, was among the first to integrate electrical stimulation, brain imaging, and clinical evaluation within the same patient group. It demonstrated that personalized targeting of brain networks can transform DBS outcomes compared to traditional, one-size-fits-all stimulation. In addition to epilepsy, researchers believe this patient-specific DBS approach could be applied to other neurological and psychiatric conditions, including depression, addiction, and stroke recovery.

“This is a major step toward making brain stimulation more effective for people with treatment-resistant epilepsy,” said lead author Arianna Damiani, M.Sc. “This isn’t just a treatment, this is your treatment.”

Related Links:
University of Pittsburgh
UPMC


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.